CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas-Reference-Cited by-同舟云学术

CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas

Published:2021-11 Issue:11 Volume:27 Page:910.e1-910.e11
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Cao Yang^ORCID,Xiao Yi,Wang Na,Wang Gaoxiang,Huang Liang,Hong Zhenya,Meng Li,Zhou Xiaoxi,Wang Jue,Yang Yang,Xu Hao,Zhang Shangkun^ORCID,Xiao Min,Chen Liting,Zheng Miao,Li Chunrui^ORCID,Mao Xia,Gu Chaojiang,Zhang Tongcun,Zhang Yicheng,Zhou Jianfeng

Funder

National Natural Science Foundation of China

Natural Science Foundation of Hubei Province

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference36 articles.

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma;Philip;N Engl J Med,1995

2. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2010

3. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party;Robinson;Bone Marrow Transplant,2016

4. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation;Svoboda;Bone Marrow Transplant,2006

5. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma;Sauter;Blood,2015

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B related cirrhosis;2024-08-10

2. CAR-T cell combination therapies in hematologic malignancies;Experimental Hematology & Oncology;2024-07-18

3. The notable outcomes of modified thiotepa-based conditioning followed by autologous stem cell transplantation in primary central nervous system lymphomas: A real-life pilot study;2024-05-31

4. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma;Cytotherapy;2024-05

5. The potential and promise for clinical application of adoptive T cell therapy in cancer;Journal of Translational Medicine;2024-05-01